PolyGene AG is an established as well recognized leading company in the field of genome engineering. Transgenic technologies are experiencing a dramatic change; TALENs and CRISPR/Cas9 increasingly replace traditional technologies such as homologous recombination in ES-cells.
Appreciating this as a chance, PG early on adapted sequence specific nucleases to its daily gene targeting business. To further increase its market share, PG wants to exploit CRISPR/Cas9 technology even further, along with the technologies developed within SwitchItOn. SwitchItOn will deliver regulatory sequences and plasmids allowing to regulate transgenes, and also genes within the genome of cells and animals.
Applying CRISPR/Cas9, regulatory switches (e.g. operator elements) can be targeted sequence specifically anywhere into the genome, making it possible to regulate entire regulatory signaling networks at will. For PG, such innovative gene regulation systems are USPs that will clearly place PG ahead of its competitors.